Hainan, China

Time filter

Source Type

Ding H.X.,China Pharma | Liu K.K.-C.,Pfizer | Sakya S.M.,Pfizer | Flick A.C.,Pfizer | O'Donnell C.J.,Pfizer
Bioorganic and Medicinal Chemistry | Year: 2013

New drugs are introduced to the market every year and each represents a privileged structure for its biological target. These new chemical entities (NCEs) provide insights into molecular recognition and also serve as leads for designing future new drugs. This review covers the synthesis of 26 NCEs that were launched in the world in 2011. © 2013 Elsevier Ltd. All rights reserved.


Jiang T.,China Pharma
Zhong yao cai = Zhongyaocai = Journal of Chinese medicinal materials | Year: 2011

To study the constituents from the root of Liriope platypgylla. Six chemical constituents were isolated from the chloroform fraction and n-BuOH fraction from EtOH extract of Liriope platyphylla. Their structures were elucidated as beta-sitosterol-3-O-beta-D-glucopyranosile(I), palmic acid (II), ruscogenin (III), LP-C(IV), LP-D(V), 25 (S) -ruscogenin 1-O-beta-D-xylopyranoside-3-O-alpha-L-rhamnopyranoside (VI), respectively. All these compounds are isolated from this plant for the first time.


Hombhanje F.W.,Divine Word University | Huang Q.,China Pharma
Pharmaceuticals | Year: 2010

With the rapidly spreading resistance of Plasmodium falciparum to available non-artemisinin antimalarial drugs, new and novel pharmaceuticals are needed. ARCO® is a new generation ACT, one of several artemisinin-based combinations developed in China to counter antimalarial drug resistance. ARCO® is a derivative of two independently developed antimalarials, artemisinin and naphthoquine phosphate, which were combined to form the artemisinin-naphthoquine combination. Both artemisinin and naphthoquine drugs have proven to be efficacious, safe and well tolerated as monotherapies. The artemisinin- naphthoquine combination offers a novel advantage over existing ACTs: it can be administered as a single oral dose (or a 1-day treatment). Several therapeutic studies conducted recently indicate that a single oral dose administration of artemisinin- naphthoquine combination is equally effective and safe as the 3-day treatment with artemether-lumefantrine combination and other existing ACTs. This would make ARCO® the next generation ACT for the treatment of uncomplicated falciparum malaria. © 2010 by the authors; licensee MDPI, Basel, Switzerland.


HAIKOU, China, Nov. 7, 2016 /PRNewswire/ -- China Pharma Holdings, Inc. ("China Pharma") (NYSE MKT: CPHI), an NYSE MKT listed corporation with its fully-integrated specialty pharmaceuticals subsidiary based in China, today announced that it plans to hold its third quarter 2016 earnings...


News Article | November 15, 2016
Site: www.prnewswire.com

HAIKOU, China, Nov. 15, 2016 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE MKT: CPHI) ("China Pharma," the "Company" or "We"), an NYSE MKT listed corporation with its fully-integrated specialty pharmaceuticals subsidiary based in China, today announced financial results for the...


HAIKOU, China, Nov 7, 2016 /PRNewswire/ -- China Pharma Holdings, Inc. ("China Pharma") (NYSE MKT: CPHI), an NYSE MKT listed corporation with its fully-integrated specialty pharmaceuticals subsidiary based in China, today announced that it plans to hold its third quarter 2016 earnings conference call on Tuesday, November 15, 2016 at 8:30 a.m. ET. Listeners may access the call by dialing 1-866-519-4004 or 65-671-350-90 for international callers, Conference ID # 14850461. A replay of the call will be accessible through November 23, 2016 by dialing 1-855-452-5696 or 61-281-990-299 for international callers, Conference ID # 14850461. China Pharma Holdings, Inc. is a specialty pharmaceutical company that develops, manufactures and markets a diversified portfolio of products focused on conditions with a high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective, high-margin business model is driven by market demand and supported by new GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network across all major cities and provinces in China. The Company's wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province. For more information about China Pharma Holdings, Inc., please visit http://www.chinapharmaholdings.com. The Company routinely posts important information on its website. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cphi-to-hold-third-quarter-2016-earnings-conference-call-on-tuesday-november-15-2016-at-830-am-et-300358137.html


Weihong Hsing discussed global IP trends with pharma and biotech leaders in China Philadelphia, PA, December 21, 2016 --( Held Nov. 17 and 18 in Shanghai, the summit presented an overview of the latest trends in IP protection legislation and provided policy updates from the United States Patent and Trademark Office (USPTO), the European Patent Office (EPO), and the State Intellectual Property Office of the P.R.C. (SIPO). Featured speakers included experienced IP attorneys and IP business leaders from Chinese and multinational corporations. Hsing acted as a co-chair of the conference. In addition, she also moderated a panel entitled “Interpretation Patent Dance of BPCIA and Its Influences on Biosimilars and Innovative Drugs.” A partner at Panitch Schwarze, Hsing specializes in patent-related issues in the biotechnology and pharmaceutical arts. Her practice involves the preparation and prosecution of patent applications, IP due diligence in mergers & acquisitions, opinion work on patent validity and infringement, rights to operate and patentability analyses, as well as technical support for patent litigation. Prior to switching to the private practice of law, Hsing worked as a patent manager at Johnson & Johnson, where she drafted and prosecuted patent applications, undertook patent and prior art analysis, and assisted in strategic counseling and patent portfolio development and management. Before starting her legal career, she was a research scientist at Princeton University and a senior scientist at a biotech start-up company. She also served as an adjunct professor for an IP licensing course at Temple Law School. To learn more, visit the firm’s website. About Panitch Schwarze Belisario & Nadel LLP – Panitch Schwarze Belisario & Nadel LLP is a boutique intellectual property law firm with offices in Philadelphia and Wilmington, Delaware. The firm’s IP law practitioners provide strategic litigation, licensing and counseling service relating to patents, trademarks, copyrights and trade secrets, domain names and internet issues domestically and internationally. The firm’s long-standing relationships with a network of associates worldwide enable its attorneys and advisors to provide clients with global intellectual property advice and protection. Philadelphia, PA, December 21, 2016 --( PR.com )-- Panitch Schwarze Belisario & Nadel intellectual property attorney Weihong Hsing, Ph.D., recently participated in the China Pharma Intellectual Property Summit 2016.Held Nov. 17 and 18 in Shanghai, the summit presented an overview of the latest trends in IP protection legislation and provided policy updates from the United States Patent and Trademark Office (USPTO), the European Patent Office (EPO), and the State Intellectual Property Office of the P.R.C. (SIPO). Featured speakers included experienced IP attorneys and IP business leaders from Chinese and multinational corporations.Hsing acted as a co-chair of the conference. In addition, she also moderated a panel entitled “Interpretation Patent Dance of BPCIA and Its Influences on Biosimilars and Innovative Drugs.”A partner at Panitch Schwarze, Hsing specializes in patent-related issues in the biotechnology and pharmaceutical arts. Her practice involves the preparation and prosecution of patent applications, IP due diligence in mergers & acquisitions, opinion work on patent validity and infringement, rights to operate and patentability analyses, as well as technical support for patent litigation.Prior to switching to the private practice of law, Hsing worked as a patent manager at Johnson & Johnson, where she drafted and prosecuted patent applications, undertook patent and prior art analysis, and assisted in strategic counseling and patent portfolio development and management. Before starting her legal career, she was a research scientist at Princeton University and a senior scientist at a biotech start-up company. She also served as an adjunct professor for an IP licensing course at Temple Law School. To learn more, visit the firm’s website.About Panitch Schwarze Belisario & Nadel LLP – Panitch Schwarze Belisario & Nadel LLP is a boutique intellectual property law firm with offices in Philadelphia and Wilmington, Delaware. The firm’s IP law practitioners provide strategic litigation, licensing and counseling service relating to patents, trademarks, copyrights and trade secrets, domain names and internet issues domestically and internationally. The firm’s long-standing relationships with a network of associates worldwide enable its attorneys and advisors to provide clients with global intellectual property advice and protection. Click here to view the list of recent Press Releases from Panitch Schwarze Belisario & Nadel, LLP


News Article | November 15, 2016
Site: en.prnasia.com

HAIKOU, China, Nov 15, 2016 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE MKT: CPHI) ("China Pharma," the "Company" or "We"), an NYSE MKT listed corporation with its fully-integrated specialty pharmaceuticals subsidiary based in China, today announced financial results for the quarter ended September 30, 2016. "The China Food and Drug Administration ('CFDA') issued 'Notice on Rectification Against Illegal Operation on Drug Logistic & Distribution' on May 3, 2016. As it had become the top priority for all pharmaceutical distributors to take measures to comply with this government policy, their time and efforts had been arranged around the inspection from CFDA, which delayed their ordinary promoting practices, purchase and distribution activities. Those significant negative impact upon distributors had continued in the three months ended September 30, 2016. which also impacted the sales performance in the third quarter of upstream suppliers like us." said Ms. Zhilin Li, China Pharma's Chairman and CEO. Ms. Li continued, "With the implementation of Consistency Evaluation on Quality and Efficacy of Generic Drugs, as well as the CFDA rectification, we continued to feel the pressure from macro-environment on our industry. In addition, the government's healthcare-price-controls also maintained continuous pressure upon our sales. Although we believe that the pharmaceutical industry is still facing a lot of challenges, with the continuous improvement of the national pharmaceutical management system and pharmaceutical companies to enhance their own strength, as well as China's huge pharmaceutical consumer market, the pharmaceutical industry still has bright prospects for development." Revenue decreased by 30.2% to $3.1 million for the three months ended September 30, 2016, as compared to $4.5 million for the three months ended September 30, 2015. This decrease was primarily due to the rectification and standardization upon drug distributors by CFDA as discussed above, whose significant negative impact upon distributors had continued in the three months ended September 30, 2016, which also impacted the sales performance in the third quarter of upstream suppliers like us. In addition, the government's healthcare-price-controls also maintained continuous pressure upon our sales. For the three months ended September 30, 2016, our cost of revenue was $2.7 million, or 86.3% of total revenue, which represented a decrease of $1.0 million from $3.7 million, or 83.1% of total revenue, in the same period of 2015. The decrease in cost of revenue during the third quarter of 2016 was due to the revenue decrease. We have had decreases in the sales estimates between the time when raw materials were purchased and the time when the sales performance is realized for certain products. We assess the inventory obsolescence levels on a quarterly basis. As a result, we determined that certain inventory was slow moving or obsolete. Based on the developed estimates, we recognized an inventory obsolescence expense of $0.1 million and $0.4 million for the three months ended September 30, 2016 and 2015, respectively. Gross profit was $0.3 million for each of the three months ended September 30, 2016 and 2015. Our gross profit margin in the third quarter of 2016 was 11.2% compared to 7.2% in the same period 2015. Without the effect of inventory obsolescence, management estimates that our gross profit margin would have been approximately 13.8% in the third quarter of 2016 and 17.0% in the third quarter of 2015. The decrease in gross profit margin was mainly because the Company sold more products with lower gross margin in this period. Our selling expenses for the three months ended September 30, 2016 was $0.9 million, which accounted for 29.7% of the total revenue in the third quarter of 2016, as compared to $1.0 million for the same period 2015, which accounted for 25.8% of the total revenue in the third quarter of 2015. Despite the decrease in sales, we still need to maintain personnel and continue our sales activities to support the sales and collection of accounts receivable, therefore our selling expenses did not decrease proportionally to our sales. Our general and administrative expenses for the three months ended September 30, 2016 were $0.3 million as compared to $0.4 million in the three months ended September 30, 2015. General and administrative expenses accounted for 9.4% and 8.6% of our total revenues in the third quarter of 2016 and 2015, respectively. Our bad debt benefit for the three months ended September 30, 2016 was $0.1 million, compared to bad debt benefit of $3.2 million in the three months ended September 30, 2015. The change was due to our revision of estimate of allowance for doubtful accounts, which resulted in the decrease in aged accounts receivable balance that had not been allowed prior to the third quarter 2015, and therefore incurred the bad debt benefit in that period. During the third quarter of 2016, the Company reviewed the contracts relating to advances made for purchases of intangible assets with independent laboratories and determined that the advances made by the Company for one formula to one of the independent laboratories were impaired. As a result, the Company recognized an impairment loss for the advances made to this laboratory in the amount of $644,696. Net Loss for the three months ended September 30, 2016 was $1.7 million, or loss per basic and diluted common share of $0.04, compared to net income of $2.9 million for the three months ended September 30, 2015, or net income per basic and diluted share of $0.07. The change in the net result was mainly due to the decrease in revenues, impairment loss and lower subsidy income in the third quarter of 2016 as compared to the same period of 2015. For the nine months ended September 30, 2016, our sales revenue was $10.3 million, which represented a decrease of $5.5 million, or 35%, from the $15.8 million in the corresponding period of 2015. This decrease was primarily due to several missed provincial tenders back in 2014 due to the fact that our new GMP certificates were not received until November 2014. As a result, we lost related market shares and negatively impacted sales afterwards. To be specific, the original tender practice actually lasted until April 2015 given the necessary process and timing of tender. The sales decrease in the nine months ended September 30, 2016 compared to its corresponding period in 2015 reflected the outcome of that event. In addition, the government's healthcare-price-controls also maintained continuous pressure upon our sales. Gross profit for the nine months ended September 30, 2016 was $1.5 million, compared to $1.3 million in the same period of 2015. Gross profit margin for the nine months ended September 30, 2016 and 2015 were 14% and 8%, respectively. Without considering the effect of inventory obsolescence, management estimates that our gross profit margin would have been approximately 16% for the nine months ended September 30, 2016 and 20% for the nine months ended September 30, 2015. Our operating loss for the nine months ended September 30, 2016 was approximately $5.1 million, compared to $8.3 million for the same period of 2015, which represented an improvement of $3.2 million. The decrease in operating loss was primarily due to lower inventory obsolescence and lower bad debt expense in the current period as compared to the corresponding period in the prior year. Net loss was $5.8 million, or $0.13 per basic and diluted share for the nine months ended September 30, 2016, compared to $9.2 million, or $0.21 per basic and diluted share, for the same period a year ago. As of September 30, 2016, the Company had cash and cash equivalents of $3.7 million compared to $6.2 million as of December 31, 2015. Additionally, working capital decreased to $8.0 million in September 30, 2016 from $12.2 million as of December 31, 2015; and the current ratio was 1.6 times as of September 30, 2016, decreased from 2.0 times as of December 31, 2015. Our accounts receivable balance decreased to $4.0 million as of September 30, 2016 from $5.9 million as of December 31, 2015. Net cash provided by operating activities was $1.4 million in the nine months ended September 30, 2016 compared to $0.7 million for the nine months ended September 30, 2015. The Company will hold a conference call at 8:30 am ET on November 15, 2016 to discuss the results of its third quarter of 2016. Listeners may access the call by dialing 1-866-519-4004 or 65-671-350-90 for international callers, Conference ID # 14850461. A replay of the call will be accessible through November 22, 2016 by dialing 1-855-452-5696 or 61-281-990-299 for international callers, Conference ID # 14850461. China Pharma Holdings, Inc. is a specialty pharmaceutical company that develops, manufactures and markets a diversified portfolio of products focused on conditions with a high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective business model is driven by market demand and supported by new GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network across all major cities and provinces in China. The Company's wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province. For more information about China Pharma Holdings, Inc., please visit http://www.chinapharmaholdings.com. The Company routinely posts important information on its website. Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as the achievability of financial guidance, success of new product development, unanticipated changes in product demand, increased competition, downturns in the Chinese economy, uncompetitive levels of research and development, and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations except as required by applicable law or regulation. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/china-pharma-holdings-inc-reports-third-quarter-financial-results-300362787.html


News Article | October 31, 2016
Site: www.newsmaker.com.au

MarketStudyReport.com adds “China Ascorbic Acid Market Research Report 2016" new report to its research database. The report spread across 121 pages with table and figures in it. This report studies Ascorbic Acid in China market, focuses on the top players in China market, with capacity, production, price, revenue and market share for each manufacturer, covering DSM CSPC Pharma Shandong Luwei Northeast Pharma North China Pharma Aland Nutraceutical Shandong Tianli Ningxia Qiyuan Zhengzhou Tuoyang Henan Huaxing Anhui Tiger Browse full table of contents and data tables at  https://www.marketstudyreport.com/reports/china-ascorbic-acid-market-research-report-2016/ Split by product Type, with production, revenue, price, market share and growth rate of each type, can be divided into Type I Type II Type III Split by Application, this report focuses on consumption, market share and growth rate of Ascorbic Acid in each application, can be divided into Application 1 Application 2 Application 3 3 China Ascorbic Acid Manufacturers Profiles/Analysis 3.1 DSM 3.1.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 3.1.2 Ascorbic Acid Product Type, Application and Specification 3.1.2.1 Type I 3.1.2.2 Type II 3.1.3 DSM Ascorbic Acid Capacity, Production, Revenue, Price and Gross Margin (2015 and 2016) 3.1.4 Main Business/Business Overview 3.2 CSPC Pharma 3.2.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 3.2.2 121 Product Type, Application and Specification 3.2.2.1 Type I 3.2.2.2 Type II 3.2.3 CSPC Pharma 121 Capacity, Production, Revenue, Price and Gross Margin (2015 and 2016) 3.2.4 Main Business/Business Overview 3.3 Shandong Luwei 3.3.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 3.3.2 128 Product Type, Application and Specification 3.3.2.1 Type I 3.3.2.2 Type II 3.3.3 Shandong Luwei 128 Capacity, Production, Revenue, Price and Gross Margin (2015 and 2016) 3.3.4 Main Business/Business Overview 3.4 Northeast Pharma 3.4.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 3.4.2 Sept Product Type, Application and Specification 3.4.2.1 Type I 3.4.2.2 Type II 3.4.3 Northeast Pharma Sept Capacity, Production, Revenue, Price and Gross Margin (2015 and 2016) 3.4.4 Main Business/Business Overview 3.5 North China Pharma 3.5.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 3.5.2 Product Type, Application and Specification 3.5.2.1 Type I 3.5.2.2 Type II 3.5.3 North China Pharma Capacity, Production, Revenue, Price and Gross Margin (2015 and 2016) 3.5.4 Main Business/Business Overview 3.6 Aland Nutraceutical 3.6.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 3.6.2 Million USD Product Type, Application and Specification 3.6.2.1 Type I 3.6.2.2 Type II 3.6.3 Aland Nutraceutical Million USD Capacity, Production, Revenue, Price and Gross Margin (2015 and 2016) 3.6.4 Main Business/Business Overview 3.7 Shandong Tianli 3.7.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 3.7.2 Chemical & Material Product Type, Application and Specification 3.7.2.1 Type I 3.7.2.2 Type II 3.7.3 Shandong Tianli Chemical & Material Capacity, Production, Revenue, Price and Gross Margin (2015 and 2016) 3.7.4 Main Business/Business Overview 3.8 Ningxia Qiyuan 3.8.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 3.8.2 Product Type, Application and Specification 3.8.2.1 Type I 3.8.2.2 Type II 3.8.3 Ningxia Qiyuan Capacity, Production, Revenue, Price and Gross Margin (2015 and 2016) 3.8.4 Main Business/Business Overview 3.9 Zhengzhou Tuoyang 3.9.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 3.9.2 Product Type, Application and Specification 3.9.2.1 Type I 3.9.2.2 Type II 3.9.3 Zhengzhou Tuoyang Capacity, Production, Revenue, Price and Gross Margin (2015 and 2016) 3.9.4 Main Business/Business Overview 3.10 Henan Huaxing 3.10.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 3.10.2 Product Type, Application and Specification 3.10.2.1 Type I 3.10.2.2 Type II 3.10.3 Henan Huaxing Capacity, Production, Revenue, Price and Gross Margin (2015 and 2016) 3.10.4 Main Business/Business Overview 3.11 Anhui Tiger To receive personalized assistance write to us @ [email protected] with the report title in the subject line along with your questions or call us at +1 866-764-2150

Loading China Pharma collaborators
Loading China Pharma collaborators